Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 40
Summary
- Conditions
- Coronavirus Infection
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04336410
- Collaborators
- Coalition for Epidemic Preparedness Innovations
- Investigators
- Study Director: Mammen P. Mammen, Jr., MD, FACP, FIDSA Inovio Pharmaceuticals
Get Well Soon